Home | Welcome to Contract Pharma   
Last Updated Sunday, October 26 2014
Print

Galapagos, Roche End Fibrosis Alliance



Published March 8, 2013
Galapagos NV and Roche have agreed to end their alliance in fibrosis. Galapagos will receive a payment of $7.5 million for work completed in 2012. Galapagos regains worldwide rights to all fibrosis assays and the targets discovered in the alliance. The company received a total of approximately $20.8 million in upfront and milestone payments from Roche under the collaboration.
 
"We regret that Roche ended the alliance due to a strategic change, but the good news is that all assets have returned to Galapagos," said Onno van de Stolpe, chief executive officer of Galapagos. "Our plan is to find another partner to continue the search for compounds against these debilitating diseases."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On